お知らせ • Feb 10
Cowen Inc. to Report Q4, 2022 Results on Feb 17, 2023 Cowen Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 17, 2023 お知らせ • Jan 13
Cowen Inc. Announces the Demise of Jack H. Nusbaum, Director Cowen Inc. announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021. Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years. お知らせ • Jan 06
Joram Siegel Joins Cowen as Head of Fixed Income Outsourced Trading Cowen Inc. announced that Joram Siegel has joined its Outsourced Trading division as Managing Director, Head of Fixed Income Outsourced Trading. Mr. Siegel will be based in New York and report to Michael Rosen and Jack Seibald, Global Co-Heads of Prime Brokerage and Outsourced Trading. Mr. Siegel brings more than 20 years of practice in credit markets to Cowen. Prior to joining Cowen, Mr. Siegel spent six years at Mitsubishi UFJ Financial Group in New York and London, where he most recently served as Managing Director, Head of Credit Americas and Global Credit Coordinator. お知らせ • Oct 01
Cowen Grows Special Situations Group with Addition of Kenneth Garnett as Managing Director Cowen Inc. announced that Kenneth Garnett has joined the firm’s Investment Banking team as a Managing Director in the Special Situations Group. Mr. Garnett will be based in New York and report to Lorie Beers, Cowen Managing Director and Head, Special Situations & Restructuring. He brings over two decades of experience in special situation private investing, restructuring investment banking and turnaround consulting. Mr. Garnett has spent over 20 years working in private equity investing, restructuring, investment banking and turnaround consulting. For the past six years, Mr. Garnett worked at Conway MacKenzie as Managing Director, Private Fund Services. Previously, he was a Partner and Founder at Renewal Capital, a private equity fund making special situations investments in the lower middle market, as well as a partner at investment bank Gordian Group. お知らせ • Sep 16
Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for a consideration approximately $1.1 billion in cash. Merck & Co. Inc. (NYSE: MRK) entered into a definitive agreement to acquire Sirna Therapeutics Inc. (NasdaqNM: RNAI) from New Leaf Venture Partners, LLC, GGV Capital, TVM Capital Life Science Venture Capital and others for approximately $1.1 billion in cash, on October 30, 2006. Under the terms of the agreement, Merck & Co. Inc. will pay $13 for each share of Sirna Therapeutics, for a total consideration of approximately $948.5 million in cash. Also, Merck & Co. Inc. will pay a consideration of approximately $57.6 million in cash, for all the outstanding options of Sirna Therapeutics as on June 30, 2006. Each option is valued at $10 with an exercise price of $3. Merck & Co. Inc. will pay a consideration of $127.30 million in cash, for all the outstanding warrants of Sirna Therapeutics as on December 31, 2005. Each warrant is valued at $10.93 with an exercise price of $2.07.
If the agreement is cancelled, then Sirna Therapeutics will pay Merck & Co., Inc., a termination fee of $42.1 million. The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, approval by the stockholders of Sirna, resignations of the board of directors of Sirna, approval by governmental entities, consents of all third parties and other customary closing conditions. Sirna stockholders owning approximately 36% of Sirna's outstanding shares have committed to support the transaction and have entered into voting agreements. The board of directors of both Merck & Co. and Sirna has unanimously approved the agreement. The two companies expect to complete the acquisition in the first quarter of 2007. The termination fee was amended to $38 million.
Goldman, Sachs & Co. was the financial advisor and Michael J. Kennedy and Sam Zucker from O’Melveny & Myers LLP were the legal advisors for Sirna Therapeutics Inc. David N. Shine and Brian T. Mangino from Fried, Frank, Harris, Shriver & Jacobson LLP were the legal advisors for Merck & Co., Inc. on the deal. Morgan Stanley was financial advisor for Merck. Latham & Watkins LLP was the legal advisor to Goldman, Sachs & Co. Morris, Nichols, Arsht & Tunnell LLP was legal advisor for Merck & Co. The Altman Group acted as information agent to Sirna and received $10,000 as fees. Sirna agreed to pay Goldman Sachs & Co. LLC an advisory fees of approximately $13.47 million of which $3.37 million payable upon announcement of the merger and $10.1 million payable on consummation of the merger. 